v3.26.1
Schedule of Segment Reporting Information (Details) - USD ($)
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting [Line Items]    
Grant Revenue $ 278,628
Research and development    
Total research and development 333,334 402,704
General and administrative    
Depreciation 466 467
Stock based compensation 306,051 315,100
Total general and administrative 914,569 973,865
Total Operating Loss (1,247,903) (1,097,941)
Other Expense:    
Net Loss (1,300,949) (1,161,602)
Clinical Stage Biotechnology Segment [Member]    
Segment Reporting [Line Items]    
Grant Revenue 278,628
Research and development    
Clinical trial and research expenses 189,138 250,496
Insurance 39,663 47,989
Payroll and taxes 78,017 82,179
Stock based compensation 13,342 13,894
Rent and utilities 9,064 8,146
Travel and entertainment 4,110
Total research and development 333,334 402,704
General and administrative    
Depreciation 466 466
Directors fees 77,500 77,500
Donations 50,000
Insurance 35,305 26,760
Legal fees 143,351 121,022
Other general and administrative expenses 27,631 16,872
Payroll and taxes 221,673 216,713
Professional fees 109,955 158,627
Rent and utilities 5,294 4,651
Stock based compensation 292,709 301,206
Travel and entertainment 685
Foreign currency transaction losses 48
Total general and administrative 914,569 973,865
Total Operating Loss (1,247,903) (1,097,941)
Other Expense:    
Interest expense (53,046) (63,661)
Net Loss $ (1,300,949) $ (1,161,602)